Prineo (Dermabond Protape) Versus Sutures for Full-thickness Surgical Incisions

NCT ID: NCT00557947

Last Updated: 2012-07-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, controlled, randomized, multi-center clinical study of up to 80 subjects with full thickness surgical incisions. Each incision included in the study will be segmented into two halves; each half will be randomized to receive final skin closure with either Prineo (DERMABOND PROTAPE) or intradermal sutures. Subjects will be evaluated post-operatively at 24 hours (± 6 hours), 7 days (± 1 day), 12 - 25 days, and 90 days (± 10 days).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surgical Incisions

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Abdominoplasty Body Lift Plastic Surgery Skin Closure Wound Healing Dermabond

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I

Dermabond Protape-Incision segments are randomized \& patient is own control

Group Type EXPERIMENTAL

Dermabond Protape (Prineo)

Intervention Type DEVICE

cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive

II

Intradermal Suture - Incision segments are randomized \& patient is own control. Investigator selected suture on the basis of standard local practice.

Group Type ACTIVE_COMPARATOR

Suture

Intervention Type DEVICE

intradermal and topical suturing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suture

intradermal and topical suturing

Intervention Type DEVICE

Dermabond Protape (Prineo)

cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Investigator selected the intradermal suture per standard local practice. Prineo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years of age;
* Be in good general health in the opinion of the Investigator with no conditions that would significantly impact wound healing as determined by medical history and review of recent concomitant medications;
* Be scheduled for at least one full thickness surgical incision of at least 20cm in length as part of elective abdominoplasty or body lift procedures, requiring the placement of sutures in the superficial fascia and subcutaneous tissue to relieve skin tension prior to final skin closure;
* Be willing to follow instructions for incision care as instructed by the investigator, and refrain from swimming or soaking in a tub during the first 12 - 25 days of the study;
* Agree to return for all follow-up evaluations specified in this protocol \[7 days (± 1 day), 12 - 25 days, and 90 days (± 10 days)\], six (± 1 month) and twelve months (± 1 month)\];
* Agree not to schedule any additional elective surgical procedures that involve an incision that is randomized for inclusion in this study, until their participation in this study is complete; and
* Sign the informed consent.

Exclusion Criteria

* Have peripheral vascular disease;
* Have insulin dependent diabetes mellitus;
* Be known to have a blood clotting disorder;
* Be receiving antibiotic therapy for pre-existing condition or infection;
* Be known to be HIV-positive or otherwise immunocompromised;
* Have known personal or family history of keloid formation or hypertrophy;
* Be currently taking systemic steroids;
* Have known or suspected allergy or sensitivity to cyanoacrylate, formaldehyde, tapes or adhesives
* Have incision type or location known to have an incidence of cyanosis or other healing abnormalities; and
* Be participating in any current clinical trial or have participated in any clinical trial within 30 days of enrolment in this study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ethicon, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Helen Colquhoun, MD

Role: STUDY_DIRECTOR

Pleiad Devices

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ

Ghent, , Belgium

Site Status

Dreifaltigkeits-Krankenhaus

Cologne, , Germany

Site Status

Markus Krankenhaus

Frankfurt, , Germany

Site Status

Akademikliniken

Stockholm, , Sweden

Site Status

Mid Essex Hospital

Broomfield, Essex, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06CS005

Identifier Type: -

Identifier Source: org_study_id